Lyell Immunopharma (LYEL) Retained Earnings (2020 - 2026)
Lyell Immunopharma (LYEL) reported Retained Earnings of -$9000.0 for Q1 2026, up 100.0% on a YoY basis from -$4500.0 in Q1 2025, and down 103.72% sequentially from $242000.0 in Q4 2025.
Lyell Immunopharma (LYEL) Retained Earnings (2020 - 2026) Analysis & Trends
Lyell Immunopharma (LYEL) has 7 years of Retained Earnings data on file, last reported at -$9000.0 in Q1 2026.
- For the quarter ending Q1 2026, Retained Earnings rose 100.0% year-over-year to -$9000.0; the trailing twelve-month figure through Mar 2026 stood at -$9000.0 (up 100.0% YoY), and the FY2025 full-year result was $242000.0, up 100.02% from the prior year.
- Retained Earnings retreated to -$9000.0 in Q1 2026, from $242000.0 in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of $1.8 billion in Q3 2025 to a low of -$1.4 billion in Q1 2025.
- A 5-year average of $9.4 million and a median of -$1.2 million in 2023 frame the typical range for Retained Earnings.
- Across the five-year window, Retained Earnings sank 1430863.83% in 2024 and soared 438097.48% in 2025, its largest moves.
- Tracing LYEL's Retained Earnings over 5 years: stood at -$767.5 million in 2022, then soared by 99.99% to -$94000.0 in 2023, then slumped by 1430863.83% to -$1.3 billion in 2024, then jumped by 100.02% to $242000.0 in 2025, then slumped by 103.72% to -$9000.0 in 2026.
- Business Quant data shows LYEL's Retained Earnings at -$9000.0 in Q1 2026, $242000.0 in Q4 2025, and $1.8 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,102.16 Bn | 67,101.87 Bn | - | -527.87 Mn |
| 2 | Nanobiotix | 1,908.96 Bn | 1,908.90 Bn | - | -27.89 Mn |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | -279.01 Mn |
| 4 | BeOne Medicines | 474.03 Bn | 469.24 Bn | 1.35 Bn | 12.91 Bn |
| 5 | Vertex Pharmaceuticals | 122.13 Bn | 114.88 Bn | 2.59 Bn | 14.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.09 Bn | 61.34 Bn | 3.31 Bn | 11.90 Mn |
| 7 | Belite Bio | 62.34 Bn | 62.34 Bn | - | - |
| 8 | Argenx Se | 55.96 Bn | 50.77 Bn | 1.41 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.53 Bn | 34.52 Bn | 959.66 Mn | -24.89 Mn |
| 10 | Lyell Immunopharma | 279.58 Mn | 279.58 Mn | - | -9,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -9,000.00 |
| Dec 31, 2025 | 242,000.00 |
| Sep 30, 2025 | 1.81 Bn |
| Jun 30, 2025 | 1.74 Bn |
| Mar 31, 2025 | -1.40 Bn |
| Dec 31, 2024 | -1.35 Bn |
| Sep 30, 2024 | 760,000.00 |
| Jun 30, 2024 | -397,000.00 |
| Mar 31, 2024 | 1.67 Bn |
| Dec 31, 2023 | -94,000.00 |
| Sep 30, 2023 | -1.18 Mn |
| Jun 30, 2023 | -2.38 Mn |
| Mar 31, 2023 | -834.44 Mn |
| Dec 31, 2022 | -767.48 Mn |
| Sep 30, 2022 | -10.00 Mn |
| Jun 30, 2022 | -688.83 Mn |
| Mar 31, 2022 | -6.60 Mn |
| Dec 31, 2021 | -1.62 Mn |
| Sep 30, 2021 | -500.66 Mn |
| Jun 30, 2021 | -451.78 Mn |